The anti-S antibody response after the first vaccine dose was greatly enhanced in individuals who had recovered from prior SARS-CoV-2 infection compared with those who were SARS-CoV-2 naive.
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Intermediate anticoagulation doses appear to be safe and effective as thromboprophylaxis in patients with high thrombotic risk active cancer.
Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.
Patients were randomly assigned 2:1 to copanlisib plus rituximab or placebo plus rituximab.
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
The cumulative 12-month incidence of venous thromboembolism was 12.7%.
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
Researchers sought to determine whether a follow-up protocol involving APN management would be beneficial for patients with multiple myeloma treated with oral chemotherapy.
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
Researchers sought to determine whether patients with cancer who had COVID-19 had an increased risk of experiencing thromboembolic events.
A novel anticancer drug derived from botanical molecules, appears to show clinical activity across a wide range of malignancies.
Adolescent survivors of childhood leukemia reported that they expect follow-up care to address support needs mostly in terms of psychosocial and emotional aspects.
Researchers sought to determine whether higher amylase levels would be linked with more advanced disease as well as inferior survival in patients with multiple myeloma.
At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.